Who is the lecturer for this upcoming JPI seminar?

The lecturer is Mr. Yasuhiro Araki, who serves as the Director of the Clinical Trial Promotion Office within the Ministry of Health, Labour and Welfare.

What is the official date and time scheduled for this seminar?

The seminar is scheduled to be held on Thursday, April 09, 2026, from 09:30 to 11:30.

What is the definition of the drug loss problem mentioned in the text?

The drug loss problem refers to a situation where medicines approved in Europe and the United States are not developed in Japan.

What are the three goals that the public and private sectors in Japan are working together to achieve?

The discussions aim to strengthen Japan's drug discovery capabilities, rapidly deliver the latest medicines to the public, and build a social system where the cycle of investment and innovation is sustained.

AI News NQ Analysis

[JPI Seminar] Ministry of Health, Labour and Welfare "Building a Drug Discovery Ecosystem and Measures to Promote Clinical Trials" to be held on Thursday, April 9th

NQ Score 50/100

AI analysis data is not yet available.

Frequently Asked Questions

Q: Who is the lecturer for this upcoming JPI seminar?: A: The lecturer is Mr. Yasuhiro Araki, who serves as the Director of the Clinical Trial Promotion Office within the Ministry of Health, Labour and Welfare.
Q: What is the official date and time scheduled for this seminar?: A: The seminar is scheduled to be held on Thursday, April 09, 2026, from 09:30 to 11:30.
Q: What is the main title of the lecture to be delivered by the speaker?: A: The title of the lecture is "The Deepening 'Drug Loss' Problem and Strengthening Japan's Drug Discovery Capabilities Ministry of Health, Labour and Welfare: Building a Drug Discovery Ecosystem and Measures to Promote Clinical Trials ~ Regulatory Harmonization and Concrete Measures for the Rapid Delivery of the Latest Medicines ~".
Q: What is the definition of the drug loss problem mentioned in the text?: A: The drug loss problem refers to a situation where medicines approved in Europe and the United States are not developed in Japan.
Q: What are the three goals that the public and private sectors in Japan are working together to achieve?: A: The discussions aim to strengthen Japan's drug discovery capabilities, rapidly deliver the latest medicines to the public, and build a social system where the cycle of investment and innovation is sustained.